2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alaninate | CAS:1911578-98-7

We serve 2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alaninate CAS:1911578-98-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alaninate

Synonyms:
2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alaninate
Remdesivir Impurity 21
 
Molecular Formula:  C21H23F5NO5P
Molecular Weight: 495.37700
 
Items of Analysis Standard of Analysis Test Results
Appearance White or almost white powder Conform
Assay(HPLC) >99.0% 99.68%
Moisture ≤0.5% 0.14%
Loss on drying ≤0.5% 0.05%
Residue on ignition ≤0.10% 0.056%
Enantiomeric DR ≤0.10% 0.0060%
Diastereomer DS ≤0.1% ND
LR <0.2% ND
Conclusion Conforms to Factory Standard
 

 
 
 



Contact us for information like 2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alaninate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Remdesivir Impurity 21 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Remdesivir Impurity 21 Use and application,Remdesivir Impurity 21 technical grade,usp/ep/jp grade.


Related News: This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?N-butyl pyridinium bromide manufacturer This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?N-BUTYLTRIMETHOXYSILANE supplier In the process of fine chemical industry transfer, intermediates are a very important category, and they are also the main link for China to undertake transfers.(L-tryptophyl-L-glutamate)(4,7-diphenyl-1,10-phenanthroline-4′,4′-disulfonate)palladium(II)(2-) vendor The man recently traveled to Wuhan, China, and sought medical care soon after his return to Massachusetts.The man recently traveled to Wuhan, China, and sought medical care soon after his return to Massachusetts.